PURE Bioscience

PURE Bioscience, Inc. is focused on developing and commercializing proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. PURE Bioscience technology platform is based on patented, stabilized ionic silver, and initial products contain Silver Dihydrogen Citrate (SDC). SDC is a broad-spectrum, non-toxic antimicrobial agent that is manufactured as a liquid and delivered in various concentrations. The Company currently manufactures and distributes SDC-based disinfecting and sanitizing products, which are registered by the United States Environmental Protection Agency. PURE Bioscience also manufactures and sells SDC-based formulations to manufacturers for use as a raw material ingredient in the production of personal care products.

Total Funding

$1.3 M

Type

Private

El Cajon, US

Founded

1992

Size (employees)

36 (est)

Website

purebio.com

PURE Bioscience was founded in 1992 and is headquartered in El Cajon, US

Report incorrect company information

PURE Bioscience Office Locations

PURE Bioscience has an office in El Cajon

El Cajon, US (HQ)

1725 Gillespie Way

Show all (1)

Report incorrect company information

PURE Bioscience Financials and Metrics

Summary Metrics

Founding Date	1992
Total Funding	$1.3 m
Latest funding size	$1.27 m
Time since last funding	2 years ago

PURE Bioscience's latest funding round in May 2016 was reported to be $1.3 m. In total, PURE Bioscience has raised $1.3 m

PURE Bioscience Financials

Summary

USD
Net income (Q2, 2018)	(4.4 m)
EBIT (Q2, 2018)	(4 m)
Cash (31-Jan-2018)	2.1 m

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cost of goods sold	565 k	344 k	285 k	441 k	760 k
General and administrative expense	5.7 m	5.1 m	4.9 m	5.1 m
R&D expense	1.3 m	1 m	790 k	927 k
Operating expense total	7 m	6.1 m	5.7 m	6 m

Quarterly

USD	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018
Cost of goods sold	45 k	111 k	65 k	54 k	48 k	116 k	265 k	134 k	132 k	146 k	307 k
General and administrative expense	1.2 m	1.2 m	1.2 m	1.1 m	1.4 m	1.4 m	1.3 m	1.3 m	1.3 m	1.4 m	2.9 m
R&D expense	176 k	215 k	171 k	236 k	238 k	205 k	248 k	214 k	222 k	144 k	264 k
Operating expense total	1.4 m	1.4 m	1.4 m	1.3 m	1.6 m	1.6 m	1.6 m	1.5 m	1.5 m	2.4 m	4.8 m

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	32 k	86 k	1.3 m	5.2 m	1.6 m
Accounts Receivable	18 k	47 k	189 k	263 k	297 k
Inventories				350 k	27 k
Current Assets	486 k	478 k	2 m	6.1 m	2.5 m

Quarterly

USD	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018
Cash	5.3 m	3.9 m	2.5 m	6.1 m	6.7 m	5.4 m	4.1 m	3.9 m	2.7 m	3.2 m	2.1 m
Accounts Receivable	47 k	40 k	86 k	93 k	106 k	68 k	146 k	142 k	185 k	143 k	146 k
Inventories	231 k	186 k	207 k	219 k	237 k	320 k	348 k	340 k	348 k	274 k	267 k
Current Assets	5.8 m	4.2 m	2.9 m	6.6 m	7.2 m	6.2 m	5 m	4.6 m	3.5 m	3.9 m	2.7 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(7.7 m)	(11.1 m)	(7.6 m)	(14.4 m)	(6.3 m)
Depreciation and Amortization	311 k	248 k		219 k
Inventories	149 k	(12 k)		(143 k)	27 k
Accounts Payable			560 k		426 k

Quarterly

USD	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018
Net Income	(1.9 m)	(1.7 m)	(2.1 m)	(2.8 m)	(10.9 m)	30 k	(1.7 m)	(936 k)	(1.7 m)	(2.3 m)	(4.4 m)
Depreciation and Amortization										71 k	142 k
Inventories										(1 k)	(20 k)
Accounts Payable	510 k	510 k	533 k	384 k	582 k	522 k	654 k	424 k	574 k	(38 k)	7 k